Skip to main content
main-content

Video commentaries

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.


Expert commentaries on the latest practice-influencing developments from international congresses.


ESMO Congress 2019

07-10-2019 | Prostate cancer | Video | Article

Expert comment: The STAMPEDE study

Eleni Efstathiou shares her views on the STAMPEDE analysis indicating that docetaxel may be an option for hormone-naïve prostate cancer regardless of metastatic disease burden (2:16).

07-10-2019 | Renal cell carcinoma | Video | Article

Researcher comment: A novel CXCR4 inhibitor for RCC and a novel immunotherapy endpoint

David McDermott talks through his renal cell carcinoma research exploring the use of a novel oral CXCR4 inhibitor and treatment-free survival as an alternative endpoint for immunotherapy trials (4:03).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

04-10-2019 | Non-small-cell lung cancer | Video | Article

Expert comment: The CheckMate 227 study

Sanjay Popat brings context to the CheckMate 227 data in light of the currently available options for patients with treatment-naïve, advanced non-small-cell lung cancer, highlighting the key aspects physicians need to bear in mind when considering nivolumab­ plus ipilimumab for their patients (2:20).

04-10-2019 | Renal cell carcinoma | Video | Article

Expert highlights: RCC immunotherapy at ESMO 2019

Axel Merseburger presents his round-up of the most interesting research on immunotherapy in renal cell carcinoma at the ESMO Congress 2019, including the TITAN RCC study and additional analyses from JAVELIN Renal 101 (3:14).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

04-10-2019 | Castration-resistant prostate cancer | Video | Article

Researcher comment: Cabazitaxel a new third-line option in mCRPC

Ronald de Wit tells us why the CARD trial results are likely to change the paradigm for the treatment of metastatic castration-resistant prostate cancer (3:58).

03-10-2019 | Castration-resistant prostate cancer | Video | Article

Researcher comment: PROfound improvement in outcomes with olaparib in mCRPC

The PROfound trial evaluated olaparib in metastatic castration-resistant prostate cancer ─ Maha Hussain discusses the clinical implications and practical applications of the findings (2:40).

03-10-2019 | Non-small-cell lung cancer | Video | Article

Expert comment: Brain metastases in lung cancer

Lizza Hendriks provides insight into two studies focusing on brain metastases in patients with non-small-cell lung cancer, the ASCEND-7 trial of ceritinib and an analysis of the genomic and epigenomic landscape of the metastases (4:26).

02-10-2019 | Castration-resistant prostate cancer | Video | Article

Expert comment: The CARD trial

Silke Gillessen comments on the phase IV CARD study investigating third-line cabazitaxel in men with metastatic castration-resistant prostate cancer (3:02). 

02-10-2019 | Castration-resistant prostate cancer | Video | Article

Expert comment: The PROfound trial

Eleni Efstathiou explains why the PROfound trial of the PARP inhibitor olaparib is the first step towards treating metastatic castration-resistant prostate cancer in a more precise way (3:09).

02-10-2019 | Genitourinary cancers | Video | Article

Expert highlights: Genitourinary cancers at ESMO 2019

Axel Merseburger takes us through his top picks of the genitourinary cancer research reported at the ESMO Congress 2019, including updates on the TITAN and STAMPEDE prostate cancer trials, the SORCE trial in renal cell carcinoma, and the investigation of first-line enfortumab vedotin in bladder cancer (5:33).

02-10-2019 | Non-small-cell lung cancer | Video | Article

Expert highlights: Lung and thoracic cancers at ESMO 2019

Ross Camidge comments on the advanced non-small-cell lung cancer research that caught his attention at the ESMO Congress 2019, including the FLAURA and CheckMate 227 overall survival data, and updates on brigatinib and lorlatinib (3:01).

01-10-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: Take-home messages from the CheckMate 227 trial

Solange Peters discusses the implications of the CheckMate 227 findings for the front-line treatment of advanced non-small-cell lung cancer and outlines the key next steps (3:45).

01-10-2019 | Mesothelioma | Video | Article

Researcher comment: PROMISE-meso trial fails to meet primary endpoint

Sanjay Popat reports on the trial pitting pembrolizumab against chemotherapy in relapsed malignant pleural mesothelioma and outlines possible strategies for taking immune checkpoint inhibitors forward (4:53). 

01-10-2019 | Renal cell carcinoma | ESMO 2019 | Article

Researcher comment: JAVELIN Renal 101 – combination approach for advanced RCC patients without upfront cytoreductive nephrectomy

Laurence Albiges discusses a JAVELIN Renal 101 subgroup analysis indicating that avelumab plus axitinib achieves tumor reduction in patients with metastatic renal cell carcinoma (2:30).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

30-09-2019 | Renal cell carcinoma | Video | Article

Researcher comment: TITAN-RCC findings show efficacy of tailored immunotherapy approach

Marc-Oliver Grimm talks through the results of the tailored nivolumab plus boost ipilimumab approach used in the TITAN-RCC study (3:38).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

30-09-2019 | Urothelial cancer | Video | Article

Researcher comment: IMvigor130 trial of atezolizumab in advanced urothelial cancer

Enrique Grande tells us why the IMvigor130 data, although very promising, are not quite ready for translation to the clinic yet (1:43).

30-09-2019 | Renal cell carcinoma | Video | Article

Expert comment: RCC immunotherapy – biomarker round-up

Guillermo de Velasco discusses four posters presented at the ESMO Congress 2019 focusing on biomarker analyses of the ADAPTeR, JAVELIN Renal 101 and NIVOREN GETUG-AFU 26 trials (6:07).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

29-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: Positive OS data for osimertinib in FLAURA trial

Suresh Ramalingam presents the overall survival analysis of the FLAURA trial of osimertinib in EGFR mutation-positive, advanced non-small-cell lung cancer, and discusses the options after progression on the tyrosine kinase inhibitor (1:50).

2019 World Conference on Lung Cancer

13-09-2019 | Surgery | Video | Article

Researcher comment: VIOLET results support VATS for lung cancer resection

WATCH | Eric Lim describes the findings of the VIOLET trial comparing video-assisted thoracoscopic lobectomy and open lobectomy for early-stage lung cancer (1:57).

13-09-2019 | Small-cell lung cancer | Video | Article

Expert comment: CASPIAN trial of durvalumab in SCLC

WATCH | Raffaele Califano comments on the CASPIAN trial of front-line durvalumab plus chemotherapy in extensive-stage small-cell lung cancer, and puts the findings in context of the IMpower133 study of atezolizumab in the same setting (3:30).

12-09-2019 | Screening | Video | Article

Researcher comment: ILST findings support novel eligibility criteria

WATCH | Stephen Lam discusses the interim findings from the International Lung Screen Trial indicating that changing eligibility criteria can improve identification of high-risk individuals (5:36).

10-09-2019 | Lung cancer | Video | Article

Researcher comment: Combining microRNAs and LDCT to assess lung cancer risk profiles

WATCH | Ugo Pastorino discusses the bioMILD study, which investigates a lung cancer screening program that supplements low-dose computed tomography with a blood microRNA assay (3:09).

10-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: AMG 510 for KRAS mutation-positive NSCLC

WATCH | Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the phase I trial of the novel KRAS inhibitor AMG 510, and comments on the next steps for the research (5:34).

09-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: TMB not prognostic for KEYNOTE-189 participant outcomes

WATCH | Marina Garassino reports the KEYNOTE-189 tumor mutational burden analysis and what the findings mean for this biomarker (4:03).

09-09-2019 | Non-small-cell lung cancer | WCLC 2019 | Article

Researcher comment: CheckMate 817 trial of nivolumab–ipilimumab

WATCH | Is first-line nivolumab–ipilimumab a feasible option for certain subgroups of advanced non-small-cell lung cancer patients, such as those with poor functional status? Fabrice Barlesi discusses the CheckMate 817 trial (3:32).

08-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: TMB does not predict NSCLC pembrolizumab–chemotherapy response

WATCH | Corey Langer describes the findings from the KEYNOTE-021 exploratory analysis of the relationship between response to pembrolizumab plus chemotherapy and tumor mutational burden in metastatic non-small-cell lung cancer patients (7:35).

08-09-2019 | Lung cancer | Video | Article

Expert highlights from WCLC 2019

WATCH | Advisory Board member Ross Camidge shares his top picks of the presentations at the 2019 World Conference on Lung Cancer, including the CASPIAN trial and the updated AMG 510 data (1:51).

2019 ASCO Annual Meeting

19-06-2019 | Radiotherapy | ASCO 2019 | Article

Researcher comment: Fewer AEs with proton versus photon radiotherapy

Brian Baumann presents their comparative analysis of the adverse event profiles of proton and photon radiotherapy in nonmetastatic patients receiving chemoradiotherapy with curative intent for various solid tumors, including lung cancer (5:28).

13-06-2019 | Screening | ASCO 2019 | Article

Researcher comment: Screening underserved groups with the Lung Bus

Mellisa Wheeler talks about how their mobile low dose-CT lung scanning unit – the Lung Bus – is helping to reach underserved populations in North Carolina, USA. She also comments on the issues of access to care and overscreening, and outlines the next steps (3:54).

12-06-2019 | Urothelial cancer | ASCO 2019 | Article

Expert comment: Phase II trial of enfortumab vedotin in urothelial cancer

ASCO expert Robert Dreicer gives his quick take on why the enfortumab vedotin data reported at the meeting hold so much promise for advanced urothelial carcinoma patients who have progressed on prior therapy (1:25).

12-06-2019 | Urothelial cancer | ASCO 2019 | Article

Researcher comment: Enfortumab vedotin active in advanced urothelial carcinoma

Investigator Daniel Petrylak summarizes the key results of the phase II EV-201 trial of the antibody–drug conjugate enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer (2:42).

04-06-2019 | Non-small-cell lung cancer | ASCO 2019 | Article

Expert comment: 5-year update of KEYNOTE-001

ASCO expert David Graham tells us just why he thinks the 5-year survival data from the advanced non-small-cell lung cancer patients enrolled in the phase Ib KEYNOTE-001 trial are so remarkable (1:26).

04-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Expert comment: ENZAMET and TITAN trials

Earle Burgess provides an independent commentary on the ENZAMET and TITAN results presented at the 2019 ASCO Annual Meeting, and discusses what these data mean for patients and physicians (2:57).

04-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Researcher comment: OS boost with enzalutamide in metastatic CSPC setting

Christopher Sweeney presents the main findings of the ENZAMET trial, which evaluated the impact of supplementing androgen deprivation therapy with enzalutamide in men with advanced castration-sensitive prostate cancer (3:10).

03-06-2019 | Non-small-cell lung cancer | ASCO 2019 | Article

Researcher comment: 5-year KEYNOTE-001 results show long-lasting survival for some advanced NSCLC patients

Edward Garon presents the 5-year follow-up results of the advanced non-small-cell lung cancer cohort of the phase I KEYNOTE-001 trial of pembrolizumab monotherapy (4:12).

01-06-2019 | Lung cancer | ASCO 2019 | Article

Expert highlights: Lung cancer at ASCO 2019

Advisory Board member Ross Camidge comments on his picks for the most exciting lung cancer research being presented at the 2019 ASCO Annual Meeting, including the RELAY trial and the ARROW trial of the RET inhibitor BLU-667 (3:13).

01-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Researcher comment: Apalutamide addition improves metastatic CSPC survival

Study author Axel Merseburger takes us through the TITAN trial investigating the addition of apalutamide to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting, and also addresses the key question of how physicians should choose between the available treatment options (3:03).

AACR Annual Meeting 2019

02-04-2019 | Immunotherapy | Video | Article

Researcher comment: The impact of lifestyle factors on the gut microbiome and immunotherapy response

Christine Spencer outlines her study investigating the effect of diet and supplements on gut microbiota and response to anti-PD-1 therapy in patients with metastatic melanoma, and discusses how the findings may be relevant to other tumor types (3:43).

02-04-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: Liquid biopsy noninferior to tissue biopsy for identifying genomic targets in metastatic NSCLC

Researcher Vassiliki Papadimitrakopoulou describes the findings of the prospective NILE study evaluating the clinical utility of genotyping cell-free DNA in patients with a new diagnosis of metastatic non-small-cell lung cancer (3:21).

01-04-2019 | Malignant pleural disease | Video | Article

Researcher comment: CAR T-cell therapy for malignant pleural disease

Prasad Adusumilli outlines the key results of their phase I trial showing promising safety and efficacy of a mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease, and also discusses the next steps (4:09).

01-04-2019 | Non-small-cell lung cancer | Video | Article

Expert commentary: TATTON trial – Exploring options for EGFR inhibitor-resistant NSCLC

Roy Herbst provides his views on the phase Ib TATTON study that combined osimertinib with either the MET inhibitor savolitinib or the MEK inhibitor selumetinib in the advanced, resistant NSCLC setting (2:53).

01-04-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: TATTON trial of savolitinib plus osimertinib in EGFR-mutated, MET-amplified NSCLC

Advisory board member and study author Lecia Sequist takes us through the findings of the savolitinib plus osimertinib cohort of the phase Ib TATTON trial of advanced non-small-cell cancer patients who have developed resistance to EGFR inhibitor therapy (4:48).

Image Credits